ePT--the Electronic Newsletter of Pharmaceutical Technology, Jan 13, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jan 13, 2011
News
USP Proposes Standards for Drug Labels
By Erik Greb
Last week, the US Pharmacopeia published proposed standards for the content, language, format, and appearance of prescription drug labels in an effort to enhance patient understanding and safety.
FDA Launches Industry Basics Website
By Angie Drakulich
As part of its transparency initiative, which began in June 2009, FDA launched a website during the first week of January 2011 that addresses basic questions for industry about regulated products.
Pharma Changes its R&D Strategy
By Stephanie Sutton
With dozens of prescription drugs soon to lose patent protection and few likely blockbusters in industry pipelines, drug developers are "aggressively" changing the way they do R&D, according to the Tufts Center for the Study of Drug Development (CSDD).
Week of Jan. 10, 2011: Company and People Notes: Eli Lilly and Boehringer Ingelheim Form Diabetes Pact; DSM Pharmaceutical Products Names President and CEO; and more.
Eli Lilly and Boehringer Ingelheim Form Diabetes Pact; DSM Pharmaceutical Products Names President and CEO; and more.
Regulatory Roundup: FDA Publishes CDER Presentation, and more.
FDA Publishes CDER Presentation, and more.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here